查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1614240

食道癌市場：按類型、癌症階段、治療、最終用戶分類 - 全球預測 2025-2030

Esophageal Cancer Market by Type (Esophageal Adenocarcinoma, Esophageal Squamous-Cell Carcinoma), Cancer Phase (Phase I, Phases II, Phases III), Treatment, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

根據預測，2023年食道癌市場價值為149億美元，預計2024年將達到160.8億美元，複合年成長率為8.26%，到2030年將達到259.9億美元。

食道癌市場包括旨在對抗這種侵襲性癌症的各種診斷、治療和研究方法。這部分至關重要，因為食道癌是全球第六大癌症死亡原因，需要早期發現並推動有效治療方法。應用範圍從診斷影像和切片檢查等早期診斷工具到手術干預、化療、標靶治療和新免疫療法等高級治療。最終用途市場包括醫院、癌症治療中心、診斷實驗室等。該市場的成長主要受到人口老化、胃食道逆流（GERD）、巴瑞特氏食道症盛行率上升以及吸菸和飲酒等生活方式等危險因子盛行率上升的顯著推動。微創手術的技術進步和個人化醫療的發展也是關鍵驅動力。隨著生物標記研究的進步，用於早期檢測和開發針對特定基因突變的客製化治療方法，也存在機會。投資於細胞療法和免疫查核點抑制劑等尖端治療方法研發的公司將擁有競爭優勢。挑戰包括治療費用高、早期診斷困難以及對常規治療方法有抵抗力的疾病的異質性。此外，嚴格的監管標準和廣泛的臨床測試的需要可能會抑制市場的快速滲透。創新可能集中在改進液態切片技術和利用人工智慧來提高診斷準確性和計劃治療。儘管市場充滿活力，大型製藥公司之間的競爭也很激烈，但生技新興企業也有機會利用顛覆性技術實現大躍進。強調合作研究夥伴關係和策略聯盟可能有利於提高研究能力和有效地將新治療方法商業化。

主要市場統計
基準年[2023] 149億美元
預計年份 [2024] 160.8億美元
預測年份 [2030] 259.9億美元
複合年成長率（%） 8.26%

市場動態：揭示快速發展的食道癌市場的關鍵市場洞察

食道癌市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 食道癌盛行率不斷上升，需要及時治療
    • 先進食管癌診斷技術的開發
    • 政府對癌症研究的計劃和資助
  • 市場限制因素
    • 食道癌治療的召回問題
  • 市場機會
    • 食道癌治療取得進展並獲得政府核准
    • 標靶治療和免疫治療的出現
  • 市場問題
    • 治療開發的複雜性

波特五力：駕馭食道癌市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解外部對食道癌市場的影響

外部宏觀環境因素對食道癌市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解食道癌市場的競爭格局

對食道癌市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV定位矩陣：食道癌市場供應商績效評估

FPNV定位矩陣是評估食道癌市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製食道癌市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，食道癌市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 食道癌盛行率不斷上升，需要及時治療
      • 先進食管癌診斷技術的開發
      • 政府對癌症研究的計劃和資助
    • 抑制因素
      • 食道癌藥物不利事件回憶
    • 機會
      • 獲得政府核准的食道癌藥物進展
      • 標靶治療和免疫治療的出現
    • 任務
      • 治療開發的複雜性
  • 市場區隔分析
    • 類型：因吸煙、飲酒等不良習慣導致食道鱗狀細胞癌高發
    • 治療：手術前合併化療及放射線治療
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章食道癌市場：依類型

  • 介紹
  • 食道腺癌
  • 食道鱗狀細胞癌

第7章 食道癌市場：依癌症分期

  • 介紹
  • 第一階段
  • 第二階段
  • 第三階段

第8章食道癌市場：依治療分類

  • 介紹
  • 化療
  • 放射治療
  • 外科手術

第 9 章 食道癌市場：依最終使用者分類

  • 介紹
  • 癌症研究所
  • 診斷實驗室
  • 醫院/診所

第10章美洲食道癌市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太食道癌市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲食道癌市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 舒格利單抗合併化療核准中國核准用於治療食道鱗狀細胞癌
    • 中國生物技術公司核准治療食道癌
    • 信達生物公佈ORIENT-15的最終分析結果，這是一項3期研究，研究信迪利單抗和化療聯合治療作為食道鱗狀細胞癌的一線治療
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Hikma Pharmaceuticals PLC
  • Jiangsu Hengrui Medicine Co., Ltd
  • Johnson & Johnson Private Limited
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-757B1C9CB069

The Esophageal Cancer Market was valued at USD 14.90 billion in 2023, expected to reach USD 16.08 billion in 2024, and is projected to grow at a CAGR of 8.26%, to USD 25.99 billion by 2030.

The esophageal cancer market encompasses a range of diagnostic, treatment, and research processes aimed at addressing this aggressive form of cancer. This sector is crucial as esophageal cancer is the sixth leading cause of cancer death globally, necessitating advancements in early detection and effective therapies. Its applications span from early-stage diagnostic tools, including imaging and biopsy, to advanced treatments like surgical interventions, chemotherapy, targeted therapy, and emerging immunotherapies. End-use markets include hospitals, cancer treatment centers, and diagnostic laboratories. Growth in this market is significantly influenced by an increasing prevalence of risk factors such as aging populations, rising incidence of gastroesophageal reflux disease (GERD), Barrett's esophagus, and lifestyle elements including smoking and alcohol use. Technological advancements in minimally invasive surgical procedures and the development of personalized medicine are also key growth drivers. Opportunities exist in advancing biomarker research for early detection and targeting specific genetic mutations to develop tailored treatments. Companies that invest in advanced R&D for cutting-edge treatments, including cell-based therapies and immune checkpoint inhibitors, stand to gain a competitive edge. Challenges include high treatment costs, difficulties in early diagnosis, and the heterogeneous nature of the disease making it resistant to conventional therapies. Additionally, stringent regulatory norms and requirement for extensive clinical trials can impede quick market penetration. Innovation could focus on improving liquid biopsy technologies and the use of artificial intelligence for better diagnostic accuracy and treatment planning. The market is dynamic, with strong competition among pharmaceutical giants, but also offers opportunities for biotech startups to make significant strides with disruptive technologies. Emphasizing collaborative research partnerships and strategic alliances would be beneficial to enhance research capabilities and commercialize new therapies effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 14.90 billion
Estimated Year [2024] USD 16.08 billion
Forecast Year [2030] USD 25.99 billion
CAGR (%) 8.26%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Esophageal Cancer Market

The Esophageal Cancer Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of esophageal cancer and need for timely treatment
    • Development of sophisticated esophageal cancer diagnostic techniques
    • Government initiatives and funding for cancer research
  • Market Restraints
    • Adverse recalls of esophageal cancer drugs
  • Market Opportunities
    • Advancements in esophageal cancer medications with favorable government approvals
    • Emergence of targeted therapies and immunotherapies
  • Market Challenges
    • Complexity in development of therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Esophageal Cancer Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Esophageal Cancer Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Esophageal Cancer Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Esophageal Cancer Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Esophageal Cancer Market

A detailed market share analysis in the Esophageal Cancer Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Esophageal Cancer Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Esophageal Cancer Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Esophageal Cancer Market

A strategic analysis of the Esophageal Cancer Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Esophageal Cancer Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Aurobindo Pharma Limited, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co., Ltd, Johnson & Johnson Private Limited, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc, Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Esophageal Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Esophageal Adenocarcinoma and Esophageal Squamous-Cell Carcinoma.
  • Based on Cancer Phase, market is studied across Phase I, Phases II, and Phases III.
  • Based on Treatment, market is studied across Chemotherapy, Radiotherapy, and Surgery.
  • Based on End-Users, market is studied across Cancer Research Institutes, Diagnostic Laboratories, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of esophageal cancer and need for timely treatment
      • 5.1.1.2. Development of sophisticated esophageal cancer diagnostic techniques
      • 5.1.1.3. Government initiatives and funding for cancer research
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse recalls of esophageal cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in esophageal cancer medications with favorable government approvals
      • 5.1.3.2. Emergence of targeted therapies and immunotherapies
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in development of therapeutics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: High prevalence of esophageal squamous-cell carcinoma owing to smoking, alcohol consumption, other toxic habits
    • 5.2.2. Treatment: Adoption of chemotherapy and radiotherapy in combination before surgery
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Esophageal Cancer Market, by Type

  • 6.1. Introduction
  • 6.2. Esophageal Adenocarcinoma
  • 6.3. Esophageal Squamous-Cell Carcinoma

7. Esophageal Cancer Market, by Cancer Phase

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phases II
  • 7.4. Phases III

8. Esophageal Cancer Market, by Treatment

  • 8.1. Introduction
  • 8.2. Chemotherapy
  • 8.3. Radiotherapy
  • 8.4. Surgery

9. Esophageal Cancer Market, by End-Users

  • 9.1. Introduction
  • 9.2. Cancer Research Institutes
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals & Clinics

10. Americas Esophageal Cancer Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Esophageal Cancer Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Esophageal Cancer Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sugemalimab Plus Chemo Receives Approval in China for Esophageal Squamous Cell Carcinoma
    • 13.3.2. China-based biotech receives approval for esophageal cancer treatment
    • 13.3.3. Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca plc
  • 6. Aurobindo Pharma Limited
  • 7. Bausch Health Companies Inc.
  • 8. Bayer AG
  • 9. Boehringer Ingelheim GmbH
  • 10. Bristol-Myers Squibb Company
  • 11. Cipla Inc.
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche Ltd
  • 14. GlaxoSmithKline Plc
  • 15. Hikma Pharmaceuticals PLC
  • 16. Jiangsu Hengrui Medicine Co., Ltd
  • 17. Johnson & Johnson Private Limited
  • 18. LEO Pharma A/S
  • 19. Merck & Co., Inc.
  • 20. Novartis AG
  • 21. Otsuka Pharmaceutical Co., Ltd.
  • 22. Pfizer Inc
  • 23. Sanofi S.A.
  • 24. Sun Pharmaceutical Industries Ltd.
  • 25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. ESOPHAGEAL CANCER MARKET RESEARCH PROCESS
  • FIGURE 2. ESOPHAGEAL CANCER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ESOPHAGEAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ESOPHAGEAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ESOPHAGEAL CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ESOPHAGEAL CANCER MARKET DYNAMICS
  • TABLE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ESOPHAGEAL ADENOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ESOPHAGEAL SQUAMOUS-CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASES II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASES III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 190. ESOPHAGEAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. ESOPHAGEAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023